Article Text

Download PDFPDF

Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer
  1. Sarah E Taylor1,
  2. Jennifer S Petschauer2,3,
  3. Heidi Donovan4,
  4. Allison Schorzman2,3,
  5. Juan Razo2,3,
  6. William C Zamboni2,3,
  7. Robert P Edwards1 and
  8. Kristin K Zorn5
  1. 1 Division of Gynecologic Oncology, Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, USA
  2. 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
  3. 3 UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
  4. 4 School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  5. 5 University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
  1. Correspondence to Sarah E Taylor, Division of Gynecologic Oncology, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA; taylorse2{at}


Introduction Intraperitoneal (IP) chemotherapy improves survival in ovarian cancer but its use has been limited by toxicity with cisplatin-based regimens. The primary objective of this study was to define the maximum tolerated dose and dose-limiting toxicity of intravenous (IV) oxaliplatin and IP docetaxel in women with recurrent ovarian, fallopian tube or peritoneal cancer. Secondary objectives were response rate, time to progression, symptom interference with quality of life, and pharmacokinetics.

Methods Patients received a constant dose of oxaliplatin 75 mg/m2 IV on day 1 and docetaxel escalating from 50 mg/m2 IP on day 2 every 3 weeks using a 3 + 3 design. Treatment continued until disease progression, remission, or intolerable toxicity occurred. Plasma and IP samples were taken to determine drug concentrations. Patients completed the MD Anderson Symptom Inventory weekly.

Results Twelve patients were included. The median number of cycles was 4 (range 2–6) with a median time to progression of 4.5 months. Among eight patients with measurable disease, the best responses were partial response in two patients, stable disease in five, and progressive disease in one. A total of 14 grade 3–4 toxicities were noted, most commonly hematologic. Four patients, all dose level 3, had six dose-limiting toxicities: two with prolonged neutropenia, one with infection, one with hyponatremia, and two with abdominal pain. Dose level 3 was therefore considered intolerable. The mean±SD ratio of docetaxel area under the curve (AUC) in IP fluid to AUC in plasma was 229±111. Symptom interference with life activities steadily decreased from cycle 1 to 5.

Conclusions Oxaliplatin 75 mg/m2 IV on day 1 and docetaxel 75 mg/m2 IP on day 2 was the maximum tolerated dose. Most patients had partial response or stable disease, even in a heavily pre-treated population. At this dose level, patient-reported outcomes demonstrate temporary but tolerable decrements in quality of life.

  • intraperitoneal chemotherapy
  • ovarian cancer
  • phase I

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.